UK fraud office: friend or foe of the medtech industry?
This article was originally published in SRA
Executive Summary
The director of the UK's Serious Fraud Office, Richard Alderman, has stressed his commitment to ensure the UK Bribery Act supports ethical companies that are disadvantaged by the activities of those involved in corrupt business practices. In doing so, he is encouraging whistleblowers who know of any wrongdoing to come forth.
You may also be interested in...
EU Nomenclature Mapping Project News: Will Critical Progress Be Hampered By Tensions?
It seems to be game over for anyone who might have been hoping the European Commission would do a U-turn on its decision to use the Italian CND nomenclature as the basis for communication in Eudamed, instead of the well-established GMDN. But GMDN is strong in its resolve to remain a vital global nomenclature service.
European Commission’s Missed Deadlines And Contingency Planning: Welcome To 2020!
2020 is not getting off to a good start for manufacturers needing to comply with the EU’s new Medical Device Regulation on 26 May 2020. The European Commission’s latest document seems to confirm industry’s fears about the ability of the EU’s medtech system to be ready in time.
EU Regulatory Roundup, December 2019: A Veritable Avalanche Of Key Decisions And Documents
December 2019 was a big month for far-reaching EU medtech regulatory developments that will have a significant impact on the way and speed of implementation of the Medical Device Regulation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: